🇺🇸 Optive Advanced in United States

533 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Eye Irritation — 128 reports (24.02%)
  2. Eye Pain — 72 reports (13.51%)
  3. Drug Ineffective — 61 reports (11.44%)
  4. Vision Blurred — 57 reports (10.69%)
  5. Dry Eye — 49 reports (9.19%)
  6. Cataract — 46 reports (8.63%)
  7. Ocular Hyperaemia — 37 reports (6.94%)
  8. Foreign Body Sensation In Eyes — 32 reports (6%)
  9. Visual Impairment — 26 reports (4.88%)
  10. Lacrimation Increased — 25 reports (4.69%)

Source database →

Optive Advanced in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Optive Advanced approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Optive Advanced in United States?

The University of New South Wales is the originator. The local marketing authorisation holder may differ — check the official source linked above.